

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for November 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Angita Pharma Inc.	AG-Cyclobenzaprine	FLEXERIL	CYCLOBENZAPRINE HCL	10 mg	tablet	02485419
Sandoz Canada Inc.	Sandoz Everolimus	Afinitor	EVEROLIMUS	2.5 mg	tablet	02492911
Sandoz Canada Inc.	Sandoz Everolimus	Afinitor	EVEROLIMUS	5 mg	tablet	02492938
Sandoz Canada Inc.	Sandoz Everolimus	Afinitor	EVEROLIMUS	10 mg	tablet	02492946
Taro Pharmaceuticals Inc.	Taro-Fampridine	Fampyra	FAMPRIDINE	10 mg	ER tablet	02482398

Taro Pharmaceuticals Inc.	Taro-Clobetasol Shampoo	Clobex Shampoo	CLOBETASOL PROPIONATE	0.05% w/w	topical, shampoo	02506203
Auro Pharma Inc.	AURO-Valacyclovir	Valtrex	VALACYCLOVIR	1000 mg	tablet	02405059